Contraline Executes Global Exclusive License Agreement for NES/T Male Contraceptive Gel

Graphene Ventures congratulates portfolio company Contraline on executing a global, exclusive license agreement with the Population Council for the Nestorone®/Testosterone (NES/T) male contraceptive gel.

Under the agreement, the NES/T program transitions from the Population Council to Contraline. The company will now lead late-stage clinical development, regulatory engagement, and advancement toward U.S. and international approvals. NES/T is being developed as a once-daily, reversible contraceptive for men.

The topical gel combines Nestorone®, a synthetic progestin, and testosterone to suppress sperm production while maintaining normal testosterone levels. Co-developed by the Population Council and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the U.S. National Institutes of Health, the program has completed a global Phase 2b clinical trial involving 462 couples.

With Phase 2b successfully completed, NES/T is currently the most advanced investigational male contraceptive candidate in development. Contraline has begun planning a pivotal Phase 3 clinical program, which is expected to be the first Phase 3 study of a hormonal male contraceptive.

In parallel, Contraline continues to advance its broader pipeline in male reproductive health, including its ADAM™ program focused on long-acting contraception.

Graphene Ventures is proud to support Contraline as it advances new options in reproductive health and works to expand contraceptive choice globally.

Important Safety Information: NES/T is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.